We value your privacy

We use cookies to analyze site usage and improve your experience. You can accept all, reject non-essential, or customize. See our Privacy Policy.

Metabolic Health · 8 min read

HRT plus exercise led insulin-sensitivity gains — but exercise drove the broader benefits

By Kevin Wolfe, Founder & CEO

Reviewed by Kindr Health Clinical Team

Published · Updated

Interim results from a 12-week randomized study found the largest improvement in insulin sensitivity when hormone therapy and structured exercise were combined. Exercise alone still produced major fitness and strength gains, and the findings do not establish HRT as a diabetes or weight-loss treatment.

A new study is generating an appealing headline: combine menopausal hormone therapy with exercise and metabolic health improves more than with either approach alone. The interim results, presented September 29 at the European Association for the Study of Diabetes 2026 Annual Meeting in Milan, do point in that direction. But the most useful conclusion is more grounded: structured exercise improved insulin sensitivity, strength, fitness, and fat mass whether or not hormone therapy was added.

The combination group recorded the largest observed improvement in insulin sensitivity. That is promising, not definitive. The study was small, lasted 12 weeks, measured a laboratory marker rather than diabetes outcomes, and has not yet been published as a full peer-reviewed paper.

What the researchers studied

Researchers from Ghent University randomized 84 hormone-therapy-naive women ages 45 to 65 into three groups: 30 received hormone therapy alone, 25 completed a structured exercise program alone, and 29 combined both. Participants had a body mass index between 18.5 and 30, so the findings should not automatically be extended to every postmenopausal population.

The hormone regimen used transdermal estradiol with oral progesterone. The exercise program ran three times each week and combined about 20 minutes of aerobic work with about 30 minutes of strength training. Two sessions were supervised by a physiotherapist; the third was completed at home with heart-rate monitoring.

What “better insulin sensitivity” actually means

Insulin helps move glucose from the bloodstream into muscle, liver, and other tissues. When those tissues respond less efficiently, the body must release more insulin to manage the same glucose load. That reduced response is insulin resistance, a risk factor for prediabetes and type 2 diabetes.

The study estimated insulin resistance with HOMA-IR, a calculation based on fasting glucose and fasting insulin. It is a useful research marker, but it is not the same as tracking who later develops diabetes, has a heart attack, or lives longer. A change in HOMA-IR over 12 weeks should therefore be read as an encouraging metabolic signal, not proof of disease prevention.

The headline result — and the result that matters just as much

The combined hormone-therapy-and-exercise group showed the greatest observed reduction in HOMA-IR. Exercise alone also improved the measure, while hormone therapy alone changed it relatively little in this interim analysis. The public report did not provide the complete effect sizes, confidence intervals, or statistical comparison for every insulin-sensitivity result, so it is too early to quantify how much extra benefit hormone therapy added.

Exercise delivered the clearest benefits across the study. Both exercise groups became stronger and raised peak aerobic capacity by roughly 3 to 3.5 milliliters per kilogram per minute — about one metabolic equivalent. Both also lost more fat mass than the hormone-therapy-only group. Adding hormone therapy produced a slightly larger fat-mass reduction than exercise alone, but did not add a significant benefit for fat-free mass.

What the study did not find

  • It did not show that the combination prevents type 2 diabetes. Diabetes diagnoses were not an endpoint.
  • It did not show fewer heart attacks, strokes, or other cardiovascular events.
  • It did not find significant overall differences in cardiovascular risk factors between the groups. A blood-pressure reduction in the combined group was not statistically significant between groups.
  • It did not establish hormone therapy as a weight-loss treatment.
  • It did not test every hormone formulation, dose, route, or population.

Why menopause can change glucose control

The menopause transition often coincides with a shift toward more abdominal fat, less lean mass, disrupted sleep, and lower activity. Falling estrogen may also affect how muscle, fat, and the liver respond to insulin. These forces overlap with aging, medications, genetics, and everyday behavior, which is why a single hormone explanation is rarely adequate.

Earlier randomized-trial reviews have found that menopausal hormone therapy can improve insulin-resistance markers in some healthy postmenopausal women, but results vary by regimen and study. A 2023 review of trials comparing combined exercise and hormone therapy with either treatment alone called the overall cardiometabolic evidence inconclusive. The new Ghent results add a useful randomized signal; they do not settle the question.

Should someone start HRT for insulin resistance?

Not on the basis of this study. Major menopause guidance supports systemic hormone therapy primarily for bothersome hot flashes and night sweats and for prevention of bone loss in appropriate candidates. Insulin sensitivity is not, by itself, an established reason to prescribe it.

For healthy women younger than 60 or within 10 years of menopause onset, the benefit-risk balance can be favorable when there is a recognized indication and no contraindication. The decision still depends on symptoms, age, time since menopause, uterus status, personal and family history, and the type, dose, and route of therapy. A licensed clinician should make that assessment.

The practical takeaway

  • Treat exercise as the foundation. The study used both aerobic and resistance work, three times per week, with progression and supervision rather than an occasional workout.
  • If you already have a clinical reason to consider hormone therapy, metabolic markers can be part of the broader conversation — not the sole reason to start.
  • Ask about blood pressure, lipids, fasting glucose, and A1c based on your history and routine preventive-care schedule.
  • If exercise feels unusually difficult, address barriers such as sleep disruption, hot flashes, pain, anemia, thyroid disease, or medication effects rather than assuming a lack of willpower.
  • Do not change hormone therapy or glucose-lowering medication based on a conference report.

The bottom line

This small randomized study gives researchers a stronger reason to test whether hormone therapy can amplify some metabolic responses to exercise after menopause. It does not turn HRT into a diabetes drug, and it does not diminish the central finding: women who exercised improved across multiple measures, with or without hormones. The final OPERATE trial results and a peer-reviewed publication will be needed to determine how large, durable, and clinically meaningful the added combination benefit really is.

This article is educational and is not a substitute for individual medical advice. Hormone therapy is a prescription treatment with benefits and risks that vary by person.

Sources

Menopause weight gain has a cause — and a protocol.

The metabolic slowdown of menopause is driven by estrogen-related insulin resistance, cortisol, and muscle loss. The kindr Metabolic Reset addresses all three.

See the Metabolic Reset →On a GLP-1? Start here →
Prescription weight care → talk to a physician

Medically reviewed by Kindr Health Clinical Team
Last updated: September 30, 2026

More on weight & metabolic health

Continue across the Kindr entity graph

Related evidence, peptides, and clinical tools on the same topic.

This content is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.

Keep reading

Research

Hormone therapy dispensing has more than doubled: what the new JAMA data mean for you

A new JAMA analysis of pharmacy dispensing, as reported by Science News, finds monthly hormone therapy dispensing to women aged 40 to 74 more than doubled since 2023, with growth in transdermal and vaginal estrogen while pills stayed flat, and we look at what that means for planning care

Research

Menopause equity: why so many women still fall through the cracks, and how to get the care you deserve

An AMWA position paper names gaps that still keep people from menopause care: training, screening, coverage, research and stigma. We look at what's changing in state law, a new academic post in British Columbia, and ACOG's guidance, and we offer a practical checklist for getting evaluated.

Research

Menopause care is going mainstream in state law: what's changing on coverage, education and work

Statehouses are moving on menopause coverage, education and work: what Illinois has enacted, what is pending in Pennsylvania, and what to ask your insurer. A federal survey also shows how few symptomatic women ages 40 to 60 currently take a prescription, and we look at how ACOG's new guidance fits in.

Explore your next step

Kindr Care is being updated, and the exact clinical process will depend on the current care pathway.

Explore care options →